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Abstract 
 
Rheumatoid arthritis (RA) is an autoimmune disease that causes painful inflammation of the 
synovium of the patient’s joints. However, current treatments for RA have a variety of 
drawbacks. They often are ineffective, expensive, invasive, risky, cause an immune response, 
and/ or only provide short term relief. Thus, we developed a new treatment for preventing 
inflammation: TNF-receptors anchored onto exosome surfaces. Exosomes are nanovesicles that 
are naturally secreted by most of the cells in our bodies. The many benefits of using exosomes 
include non-immunogenicity, natural stability in the body, and non-invasiveness. We have 
demonstrated that exosome membrane bound TNF-receptors have the ability to prevent 
inflammation in mammalian cells. The success of this project could lead to a clinically effective 
treatment of rheumatoid arthritis as well as other inflammatory diseases by opening the doors to 
further research and development of exosomal therapies.  
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1. Introduction 
 
1.1. Background and Motivation: Developing a new treatment for rheumatoid 
arthritis 
 
The problem we sought to address was inflammation in rheumatoid arthritis (RA). Currently, the 
options for RA treatment are limited and each has their own drawbacks. Exosomes, however, are 
a promising potential candidate for inflammation treatment with a variety of benefits. 
Rheumatoid arthritis is a chronic autoimmune disorder where the host’s immune system 
attacks its own synovium, the lining of the joint membranes. This causes inflammation of the 
synovium that not only causes pain, but also bone erosion and joint deformity. Approximately 35 
- 70 million people are afflicted with RA worldwide and so it is an important focus for furthering 
treatment development.1 
Current treatments such as surgery and disease modifying anti-rheumatic drugs (DMARDs) 
are not fully effective. Newer biologic therapies are generally quite expensive, demand frequent 
dosing, and pose some severe safety concerns including immune responses and high risk of 
infection. Our research sought to develop a treatment that would overcome these drawbacks and 
alleviate pain and damage in RA patients. 
 
1.2. Literature Review: Rheumatoid arthritis and the therapeutic potential of 
exosomes 
 
1.2.1. Rheumatoid arthritis 
1.2.1.1. Role of TNFα in rheumatoid arthritis 
Preventing inflammation, the primary cause of joint pain and damage in RA, is 
the primary focus of treating patients with RA. This swelling occurs as part of an 
inflammation pathway, which is often a signaled response to injury and a part of 
the body’s natural healing process. The pro-inflammatory cytokines that are 
                                                        
1 "8 Things People with Rheumatoid Arthritis Want You to Know." Roche -. F. Hoffmann-La Roche Ltd, 2016. 
Web. 
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directly involved in the inflammation pathway in RA can be rapidly generated and 
are done so in a specific order that dictates the effect each cytokine has on the 
inflammatory response. The most rapidly responding of these is tumor necrosis 
factor α (TNFα), which is produced and secreted in the first hour of stimulation, 
followed an hour later by interleukin 1 and 6 (IL-1 and IL-6)2. Within the 
rheumatoid synovium, or affected joint cavity of a patient with RA, there is a 
much higher concentration of these three cytokines than in non-pathogenic 
synovial fluid. Studies have found that by blocking these cytokines, a significant 
reduction of inflammation occurs. It was also shown that blocking TNFα inhibited 
the downstream upregulation of both IL-1 and IL-6 due to the specific order of 
cytokine release and was thus sufficient for inflammation reduction. 3 
1.2.1.2. Current treatments and their drawbacks 
The following section further details the current treatments and their drawbacks 
which are summarized in the table below. 
 
Table 1-1: Drawbacks of current RA treatments. 
Current Treatment Drawbacks 
Surgery: synovectomy or joint replacement  • Invasive 
• General surgical risks 
Disease-modifying antirheumatic drugs (DMARDs) • History of failure 
• Insufficient alone 
Anti-TNFα antibody injections (Adalimumab) • Immune response 
• Short term & expensive 
Soluble TNF-receptor (sTNFR) injections 
(Etanercept) 
• Risk of infection and tumorigenesis 
• Short term & expensive 
 
As the table indicates, each option has significant drawbacks. 
Surgery is invasive, expensive, and increases the risk for further damage. 
It is also ineffective at preventing further development of RA, and is solely useful 
for repairing damages already incurred by severe inflammation. DMARDs have 
significant side effects, must be taken multiple times a week, and are ineffective 
                                                        
2 Feldmann, M., Brennan, F., Williams, R., & Maini, R. (2004). Definition of TNFα as a therapeutic target for 
rheumatoid arthritis. TNF-Inhibition in the Treatment of Rheumatoid Arthritis, 1-22. 
3 Feldmann, M., Brennan, F., Williams, R., & Maini, R. 1-22. 
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when given alone. They are often used in tandem with biologic TNFα-inhibiting 
drugs.  
 
Adalimumab is an anti-TNFα chimeric antibody that triggers an immune 
response to remove TNFα by natural processes, but it has a risk of over 
stimulating your immune system.4 Chimeric antibodies, built from both human 
and mouse genes, have been known to elicit unwanted immune responses due to 
their foreign nature. This immune response includes the development of naturally 
produced antibodies that target Adalimumab, thus reducing its long-term effect. 
Etanercept, upon which we have built the concept of our solution, is a soluble 
TNF-receptor (sTNFR1) that binds to TNFα and preventing it from initiating the 
inflammation pathway.5  
Current TNFα inhibiting medications are released into the entire blood 
stream and put the patient at high risk of serious infection and increased risk of 
cancerous tumorigenesis. Both TNFα inhibiting medications have been shown to 
be successful and efficacious; however, they each cost over $3,000 per month and 
are often administered bi-weekly by subcutaneous injection. Because of these 
problems, many patients diagnosed with RA are still suffering or are at risk for 
more serious health concerns.  
 
 
1.2.2. Exosomes as a potential solution 
1.2.2.1. Definition and therapeutic potential of exosomes 
Exosomes are extracellular nanovesicles that are naturally secreted by most of the 
cells in the body for transportation and communication between cells.6 Using 
exosomes as a therapy is a novel strategy with a variety of benefits that address 
the issues of current RA treatments (Table 1-2). 
                                                        
4 Putte, L. V., Salfeld, J., & Kaymakçalan, Z. (2004). Adalimumab. TNF-Inhibition in the Treatment of Rheumatoid 
Arthritis, 71-88. 
5 Sule, S., & Bathon, J. (2004). Etanercept. TNF-Inhibition in the Treatment of Rheumatoid Arthritis, 47-69. 
6 Stickney, Z., Losacco, J., McDevitt, S., Zhang, Z., & Lu, B. (2016). Development of Exosome Surface Display 
Technology in Living Human Cells. Biochemical and Biophysical Research Communications, 472(1), 53–59. 
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Table 1-2: How exosomes overcome the many drawbacks of current RA treatments. 
Current Treatment Drawbacks Exosomal Solution 
Surgery: 
synovectomy or joint 
replacement  
• Invasive 
 
• General surgical 
risks 
• Noninvasive, injection based 
administration 
• Permanent tissue damage would not 
occur  
Disease-modifying 
antirheumatic drugs 
(DMARDs) 
• History of failure 
 
• Insufficient alone 
• Founded upon most robust current 
treatment option (sTNFR) 
• No combination therapy needed 
Anti-TNFα antibody 
injections 
(Adalimumab)3 
• Immune response 
 
• Short term & 
expensive 
• Naturally produced- exosomes 
elicit no immune response 
• Natural stability in the body 
extends duration of efficacy 
Soluble TNF-
receptor (sTNFR) 
injections 
(Etanercept)4 
• Risk of infection and 
tumorigenesis 
 
• Short term & 
expensive 
• Local Short term & expensive 
administration would maintain 
normal levels of systemic TNF 
• Natural stability in the body extends 
duration of efficacy 
 
 
As demonstrated in Table 1, exosomes have great therapeutic potential. However, 
these nanovesicles would require modification for a specific goal. For treating 
inflammation in rheumatoid arthritis, we modified the surface of the exosome 
with TNF-receptors to occupy the TNFα that initiates the inflammation pathway 
in RA. Considering the potential benefits above, this proposed solution would 
hopefully be able to navigate the affected synovial joint easily, provide long term 
relief, and would not cause any immune response, unlike current treatment 
options. 
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1.2.2.2. Exosome surface engineering  
Exosomes are formed through an endocytic pathway7,8,9 (Figure 1-1).  
Figure 1-1: Exosome biogenesis. 
 
As shown in the figure above, the proteins on the exosome membrane 
originate from the cellular membrane. Proteins destined for the exosome will self-
organize within the cellular membrane, and this specialized domain invaginates to 
form an endosome with the same proteins. This endosome invaginates further, 
forming an endosome containing many smaller vesicles, otherwise known as a 
multivesicular body (MVB). Upon fusion of the MVB to the plasma membrane, 
exosomes are secreted out of the cell.10 
The knowledge of this pathway allows engineers to manipulate surface 
expression by modifying the proteins that are known to localize onto exosome 
membranes. One method of modifying membrane proteins is by changing the 
DNA sequence that codes for the target membrane protein, so that the structure of 
                                                        
7 Babst, M. (2011). MVB vesicle formation: ESCRT-dependent, ESCRT-independent and everything in between. 
Current Opinion in Cell Biology, 23(4), 452–457. 
8 Hurley, J. H., Boura, E., Carlson, L. A., & Rycki, B. (2010). Membrane budding. Cell, 143(6), 875–887. 
9 Théry, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature 
Reviews. Immunology, 2(8), 569–579. 
10 Théry, C., Zitvogel, L., & Amigorena, S. 569–579. 
MVB 
Exosomes 
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the protein can be altered to produce a desired function. Engineering the surface 
of exosomes requires targeting of proteins that are commonly found in exosomes. 
Primary molecular scaffolds for exosome surface engineering include 
glycosylphosphatidylinositol (GPI) anchored proteins and the milk fat globule-
EGF factor 8 (MFG-E8) protein found on the outer membrane, as well as 
transmembrane proteins such as tetraspanins and vesicular stomatitis virus 
glycoprotein (VSV-G).  
1.2.2.2.1. Tetraspanin CD63 as an exosome engineering scaffold 
Tetraspanins proved to be a great candidate for the display of molecules on the 
surface of exosomes because of their prevalence in exosomes. Tetraspanins are a 
membrane-bound protein, with an intrinsic membrane localization signal and play 
a role in the endocytic budding from the cellular membrane through the formation 
of tetraspanin enriched microdomains (TEMs), which explains their abundance on 
the surface of exosomes.11 Fluorescent reporters have been successfully fused 
with tetraspanin CD63 and used to track the biogenesis, secretion, and uptake of 
exosomes.12 Cells with the engineered tetraspanins secrete the modified exosomes 
into the culture medium, which can be isolated and introduced to and taken up by 
recipient cells.13 This indicates that tetraspanins can be fused with other desired 
proteins, such as a TNF-receptor, for potential therapeutic applications. Thus, we 
used this scaffold to modify the exosome surfaces with TNF-receptors for the 
potential treatment of inflammation in RA. 
 
1.2.3. Inflammation reporters  
TNFα’s effects on the inflammation pathway have been tested at the cellular level in 
various past experiments. Biosignals have been developed to measure the presence of an 
inflammatory response in a cell culture model. They target the NF-κB pathway (Figure 1-
2) as a means of identifying this response.  
                                                        
11 Hassuna, N., Monk, P. N., Moseley, G. W., & Partridge, L. J. (2009). Strategies for targeting tetraspanin proteins: 
Potential therapeutic applications in microbial infections. BioDrugs, 23(6), 341–359. 
12 Stickney, Z., Losacco, J., McDevitt, S., Zhang, Z., & Lu, B. (2016). Development of Exosome Surface Display 
Technology in Living Human Cells. Biochemical and Biophysical Research Communications, 472(1), 53–59. 
13 Stickney, Z., Losacco, J., McDevitt, S., Zhang, Z., & Lu, B. 53–59. 
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Figure 1-2: NF-κB pathway. 14 
 
The pathway begins with the binding of TNFα to the TNF-receptors on the 
exterior of the cell membrane. This activates an enzyme that activates NF-κB, a 
transcription factor consisting of p65 (RelA) and p50, which is then translocated into the 
nucleus. Once in the nucleus, NF-κB binds to the response elements just upstream of the 
gene encoding for the inflammatory response. Once bound, it induces the expression of 
this gene, yielding inflammation. 
1.2.3.1. 3T3 NF-κB p65-RFP H2B-GFP reporter 
One such reporter cell line uses a p65 knockout line of 3T3 mouse fibroblast cells 
with an added p65-RFP complex.15  The modified NF-κB pathway is displayed in 
Figure 1-3, below.  
                                                        
14 Rock Creek Pharmaceuticals Inc. NF-kB Signaling Pathway. Digital image. Securities and Exchange 
Commission. June 2015. 
15 Tay, Savas. (2011). Single-cell NF-κB dynamics reveal digital activation and analog information processing in 
cells. Nature. 466(7303), 267–271. 
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Figure 1-3: NF-κB pathway for 3T3 NF-κB reporter. The red circle represents red fluorescent protein (RFP). 
 
In the presence of TNFα, this reporter should show p65-RFP complex migration 
from the cytosol into the nucleus upon the initiation of the inflammation pathway 
as NF-κB is activated to promote the expression of inflammatory response. The 
same cell line includes a H2B-GFP nuclear marker (not shown) to assist with 
nuclear identification in imaging. (This reporter was donated to us by Dr. Savas 
Tay from University of Chicago.) 
1.2.3.2. HEK 293 NF-κB GFP/Luciferase reporter  
We contributed to the development of another reporter in a previous project in our 
lab. This reporter was designed to express both GFP and firefly luciferase in the 
presence of TNFα16 not by modifying the proteins in the NF-κB pathway, but 
rather by adding DNA coded to be a target of NF-κB. This modification is shown 
in Figure 1-4, below. 
                                                        
16 Zhang, Z., Stickney, Z., Duong, N., Curley, K., & Lu, B. (2017). AAV-based dual-reporter circuit for monitoring 
cell signaling in living human cells. Journal of Biological Engineering, 11(1), 18. 
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Figure 1-4: NF-κB pathway for HEK NF-κB GFP/Luc reporter. 
 
The reporter consists of a viral vector cassette containing transcription factor 
response elements (TREs) and a minimal CMV promoter followed by the gene 
encoding for GFP and luciferase. In our reporter cells containing this biomarker 
DNA, in the presence of TNFα, NF-κB is activated and binds to the TREs, 
leading to the expression of GFP and luciferase. 
 
1.3. Project Overview: 3 phases’ goals and expected results 
 
Our expected results for each phase of experimentation are outlined below. The actual results 
and discussion are in each phases’ respective Results and Discussion sections. 
 
1.3.1. Phase 1: Design Production 
The goal of this stage was to manufacture and harvest the modified exosomes. We expected 
that live mammalian cells could be manipulated to secrete the modified exosomes that 
could be harvested and stored for later testing of efficacy in preventing inflammation. 
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1.3.2. Phase 2: Verification of Inflammation Reporter 
In order to determine whether our design is effective in preventing inflammation, we 
needed a reliable method of detecting inflammation. Thus, the goal of this stage was to 
determine the best method in reporting inflammation. We predicted that the best reporter 
for our purposes would be one that is quantifiable, reliable, and high throughput. 
 
1.3.3. Phase 3: Testing Efficacy of Design 
The goal of this stage was to determine whether our modified exosomes are capable of 
preventing inflammation. Using the inflammation reporter verified in Phase 2, we measured 
the effect of the modified exosomes stored from Phase 1 on the inflammatory response of 
live mammalian cells. We expected our design to significantly decrease the level of 
inflammation by at least 50%.  
 
1.4. Timeline 
 
The phases described above were completed according to the following timeline. 
 
Figure 1-5: Timeline of project phases. 
 
 
1.5. Risk Managements: Potential setbacks and their work-arounds 
 
In order to optimize our success in this project, we have analyzed the potential risks that could 
contribute to the project’s failure. We had back-ups and work-arounds in place in order to avoid 
or be able to quickly recover from most of these potential risks moving forward. 
 
 
 
Phase 1: 
Design Production
Fall 2016
Phase 2: 
Verification of 
Inflammation Reporter
Winter 2017
Phase 3: 
Testing Efficacy of 
Design
Spring 2017
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Table 1-3: Analysis of project risks. 
Risk Severity Chance Solution Ease Score* 
• Failure of current design in 
preventing inflammation 
- This is an novel method of 
treating inflammation that may 
not work 
10 5 
• Use a different scaffold 
for anchoring TNFR onto 
exosome surface 
- VSV-G, GPI, or 
MFG-E8 
10 500 
• Contamination 
- Shared incubator in the tissue 
engineering lab has a recent 
history of contamination 9 3 
• Isolate our cells to one 
corner 
• More thoroughly 
decontaminate going in 
and out of incubator 
• Limit outside use of 
incubator 
5 135 
• Resource depletion 
- Certain solutions may need to 
be replenished 
- Dependent on the need for 
repetition 
7 2 
• Coordinate with other 
groups in our lab 
• Mutually applicable 
resources should be shared 
to reduce waste 
4 56 
• Team member absence 
- Kevin was abroad from 
12/10/16 - 1/9/17 2 10 
• Freeze down unnecessary 
cell lines 
• Divide labor such that 
Kevin is responsible for 
remote work 
2 40 
*Score is calculated as the product of the three ranked columns. Higher scores are areas of greater concern. 
 
1.6. Significance 
 
Our project serves as a basis for further development and testing of a novel treatment for RA. 
Using TNF-receptors on exosomes would allow for a more efficient treatment for RA without 
the side effects of current treatment options. This will directly affect the well-being of the 35-70 
million suffering with RA worldwide.  Although we have not yet established a clinically ready 
product, our research lays the groundwork for animal and clinical trials of our modified 
exosomes. In addition, our success should inspire further attempts to use exosome surface 
engineering for various other medical therapies including immunotherapies, gene therapies, 
and/or targeted drug delivery. 
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1.7. Team management 
 
With only two group members, we worked together equally in designing, executing, and 
summarizing experiments. Dr. Lu was our advisor, and as a team, all three of us met once per 
week to discuss results and upcoming experiments. 
 
1.8. Budget 
 
Outlined below is our project budget. 
 
Table 1-4: Budget.  
Flasks and plates $250.00 
Fetal bovine serum $250.00 
Serum free media $120.00 
Gene synthesis $650.00 
TNFα $210.00 
Culture Media $500.00 
Transfection Reagent $470.00 
Luciferase Assay $870 
Total Cost $3,320 
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2. Design Production 
 
 
Figure 2-1: Timeline of project phases. This chapter focuses on Phase 1. 
 
The goal of this stage was to manufacture and harvest the modified exosomes. 
 
2.1. Key constraints 
 
The key constraints for this portion of the project include the method by which we manufactured 
exosomes and the imaging technology we had access to to demonstrate exosome production. At 
the time of experimentation, our lab only had access to a fluorescent microscope, not a confocal 
microscope that would have made imaging exosomes more clear and accurate. Also, the method 
by which we harvested exosomes had a low yield and mandated many repetitions to gather 
enough exosomes for one trial of our third phase of the project. 
 
2.2. Design description 
 
Because of their prevalence on the exosome surface, we used tetraspanin CD63 as a scaffold to 
anchor TNFRs onto the exosome surface (Figure 2-2). 
 
Figure 2-2: Design for anchoring TNF-receptor onto exosome surface. The purple hexagon represents a TNF-
receptor and the green bar represents GFP anchored onto tetraspanin CD63 (left). This modified protein will be 
produced onto the exosome surface (right).  
Phase 1: 
Design Production
Fall 2016
Phase 2: 
Verification of 
Inflammation Reporter
Winter 2017
Phase 3: 
Testing Efficacy of 
Design
Spring 2017
14 
 
The TNFR functions as a sponge to soak up excess TNFα to prevent it from initiating the 
inflammation pathway in cells. The GFP enables visualization under a fluorescent microscope 
throughout the experiment. Cells with the engineered tetraspanins will secrete functional 
exosomes with the engineered tetraspanin into the culture medium, which can be isolated and 
introduced to recipient cells.  
 We also constructed a tetraspanin CD63 with a red fluorescent protein (RFP) in place of 
the TNF-receptor. This was to produce non-treatment exosomes as a control for experimentation.  
 
 
Figure 2-3: CD63-RFP-GFP construct. The bars represent red and green fluorescent proteins. 
 
Human embryonic kidney cells (HEK 293) were used to produce both the CD63-RFP-GFP and 
CD63-TNFR-GFP exosomes. 
 
2.3. Expected results 
 
We expected to see smaller green dots in the cells with the engineered tetraspanins (as opposed 
to the whole cell being green) when examining them under the GFP filter of a fluorescent 
microscope. This would confirm that our modified tetraspanins are localizing onto exosomes 
which can be harvested from the cells. 
 
2.4. Backup plan  
 
If this design fails to produce exosomes with the CD63-TNFR-GFP, we planned to pursue a 
different scaffold for anchoring the TNFR onto the exosome surface. Other possible scaffolds 
include VSV-G, GPI, and MFG-E8. 
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2.5. Materials and Methods 
 
2.5.1. Materials 
 
Table 2-1: Materials – Phase 1 
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
Dish 145mmx20mm Sigma-Aldrich/ Greiner 639160 
DMEM + 10% FBS + PS 
media* 
Created in lab N/A 
Transfection Materials 
(Appendix A3-A) 
  
CD63-TNFR-GFP plasmid GenScript N/A 
CD63-RFP-GFP plasmid  GenScript N/A 
Serum-Free Medium without L-
Glutamine 
BioWhittaker/ UltraCULTURE 12-725F 
50 mL conical-bottom 
centrifuge tubes 
VWR 89039-658 
Syringe, 5 mL BD Biosciences/ BD Luer-Lok 309646 
Hydrophobic filter, 0.2 micron BD Biosciences/ BD Influx 645270 
Exosome precipitation solution SBI/ ExoQuick EXOQ5A-1 
Phosphate-Buffered Saline pH 
7.4 (PBS) 
Thermo Fisher Scientific AM9625 
Cryogenic vials Sigma-Aldrich/ Nalgene V4757 
*Refer to Appendix A1: Making Media - DMEM + 10% FBS + PS 
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2.5.2. Special notices 
• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform this procedure unless the above requirements are met.  
 
 
2.5.3. Overview of procedure 
 
Table 2-2: Overview of procedure – Phase 1 
 Step Section 
Day 1 Seed cells 1 
Day 2 Transfect cells 2 
Day 3 
Image transfected cells 3 
Change media to serum-free medium 4 
Day 4 N/A N/A 
Day 5 Exosome Harvest Part I 5 
Day 6 Exosome Harvest Part II 6 
 
 
2.5.4. Procedure 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed HEK 
293 cells onto 2 145mmx20mm dishes at a density of 1-5x105 cells/mL with 
DMEM + 10% FBS + PS media. 
1.2. Incubate at 37°C for 24 hours. 
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Day 2 
2. Transfect Cells 
2.1. Using a transfection protocol (Appendix A3-B), transfect the cells on 1 
145mmx20mm dish from Day 1 with CD63-TNFR-GFP plasmid. 
2.2. Repeat step 2.1 for the other 145mmx20mm dish from Day 1 with CD63-
RFP-GFP plasmid. 
Day 3 
3. Image transfected cells (for cells on each dish) 
3.1. Using a fluorescent microscope take phase, GFP, and RFP images of the cells 
at 20x.  
4. Change media to serum-free medium (for each dish) 
4.1. Carefully aspirate the media off of the dish. 
4.2. Carefully add 20 mL of serum-free medium to the dish.  
4.3. Incubate at 37°C for 48 hours. 
Day 5:  
5. Exosome Harvest Part I (for each dish) 
5.1. Collect the serum-free medium into a 50mL centrifuge tube. 
5.2. Centrifuge the 50mL centrifuge tube at 1500xg for 10 minutes. 
5.3. Filter the supernatant through a 0.2-micron filter with a 5mL syringe into a 
new 50mL centrifuge tube. 
5.4. Add ¼ of the supernatant volume of exosome precipitation solution 
5.5. Incubate at 4°C for 24 hours. 
Day 6 
6. Exosome Harvest Part II (for each centrifuge tube from Day 5) 
6.1. Centrifuge the 50mL centrifuge tube from Day 5 at 3000xg for 30-45 minutes. 
6.2. Carefully aspirate off the supernatant. 
6.3. Resuspend the pellet in 50µl of PBS. 
6.4. Store in a cryogenic vial at -80°C until needed.  
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2.6. Results 
 
One day after the transfection, the cells were imaged to examine the localization of the modified 
protein. These images are displayed below. 
 
 
Figure 2-4: Exosome production of CD63-TNFR-GFP in HEK 293 cells. The nucleus is marked with a 
Hoescht stain for visualization in the last photo. 
 
2.7. Discussion 
 
The smaller green dots in the GFP images taken after the transfection demonstrate the successful 
localization of CD63-TNFR-GFP into exosomes. We were then able to harvest these exosomes 
and store them for usage in Phase 3.  
10 μm  10 μm  10 μm  
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3. Verification of Inflammation Reporter 
 
 
Figure 3-1: Timeline of project phases. This chapter focuses on Phase 2. 
 
In order to determine whether our design is effective in preventing inflammation, we needed a 
reliable method of detecting inflammation. Thus, the goal of this stage was to determine the best 
method in reporting inflammation. 
 
3.1. Key constraints 
 
The key constraints for this portion of our project were the availability, sensitivity, and 
quantifiability of methods to measure the biosignals given off by our inflammation reporters. 
Due to the nature of our various reporters, different measurement metrics were used: confocal 
imaging, flow cytometry, and a luminescence assay. We eventually selected the reporting 
mechanism that would be measured by a luciferase assay because of its highly sensitive and 
quantifiable nature and our access to the necessary equipment. 
 
3.2. Design description 
 
We tested three different reporting mechanisms for our project to get a more comprehensive look 
into where in the inflammation pathway the inflammatory response would be being inhibited by 
our therapy. 
 
3.2.1. 3T3 NF-κB reporter  
The 3T3 NF-κB p65-RFP H2B-GFP reporter cell line is an established reporter that can 
measure inflammatory response in a cell culture model. As discussed in section 1.2.3.1, the 
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initiation of the inflammation pathway is indicated by the migration of p65-bound RFP to 
the nucleus from the cytosol. We were able to roughly estimate this inflammation response 
visually using a confocal microscope. Cells that expressed cytosolic RFP were considered 
uninflamed and cells with distinct nuclear RFP were considered inflamed. The cells also 
contained the gene for H2B-GFP, which encodes for a green fluorescing nucleus. This 
allowed for more distinct visual identification of the nucleus, and helped in the process of 
roughly quantifying inflammation in a population of cells. As depicted in Figure 3-2, the 
nucleus will appear yellow in an overlay image of the green nucleus when the RFP has 
migrated into it. 
We designed an experiment to visually estimate the percentage of cells with nuclear RFP 
after treatment with TNFα. This visual change is displayed in the figure below. 
 
 
Figure 3-2: Visual change of 3T3 NF-κB reporter with exposure to TNFα. Red, green, and yellow 
represent RFP, GFP, and both RFP + GFP expression respectively. 
 
3.2.2. HEK NF-κB GFP reporter 
Using a dual reporter that we had previously helped develop (section 1.2.3.2), we were able 
to see one step after the migration of p65 into the nucleus. This reporter is measuring the 
expression of the gene downstream the NF-κB promoter region. As the cell transcribes what 
would usually be the genes coding for the inflammatory response to TNFα, it will now also 
transcribe the genes for both GFP and Firefly Luciferase. The presence of GFP was visually 
indicated by green fluorescence in the cytosol of the cell, as demonstrated in Figure 3-3. 
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Figure 3-3: Visual change of HEK NF-κB dual reporter with exposure to TNFα. Green represents GFP 
expression while the yellow burst represents luminescence (discussed in section 3.2.3).  
 
 
We were able to quantify the expression of GFP using flow cytometry, a technique that can 
measure the fluorescent intensity of each cell of a population individually. We designed an 
experiment where we used flow cytometry to measure the fluorescent intensity of our 
reporter cell line with and without TNFα addition. The results were compared to a control of 
unmodified HEK 293 cells.  
 
3.2.3. HEK NF-κB Luciferase reporter 
We then designed an experiment that utilized the second reporter protein expressed by our 
activate dual-reporter cell line: luciferase. Luciferase causes luminescence that cannot be 
detected by the naked eye. Thus, in order to measure the expression of luciferase, we lysed 
the cells and ran a luciferase assay that measures the luminescence of the firefly luciferase 
protein in a highly quantifiable format. Our experiment was designed as a dose response to 
TNFα so that we could identify the concentration of TNFα that would be most appropriate 
to test the efficacy of our therapy. The results were compared to a control of unmodified 
HEK 293 cells treated with the same TNFα doses. 
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3.3. Expected results 
 
Due to past studies done using these reporters17,18, we expected all three reporters to function. 
This entails migration of RFP to the nucleus in the 3T3 reporter, and both an increase in GFP and 
luminescence in the dual reporter in response to TNFα. We anticipated that the TNFα dose that 
would be best suited for the next phase to be somewhere between 0.1 and 10 ng/ml TNFα. 
 
3.4. Backup plan 
 
We chose to use three different reporting mechanisms to act as a back-up plan should one of 
them fail. In preparation for contamination, we made several frozen back-ups of each reporter 
cell line as well. 
 
3.5. Materials and Methods: Verifying 3T3 NF-κB reporter  
 
3.5.1. Materials 
 
Table 3-1: Materials – Phase 2 – Verifying 3T3 NF-κB reporter  
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
4 chamber glass bottom dishes Cellvis D35C4-20-0-N 
DMEM + 10% FBS + PS media* Created in lab N/A 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
Serum-Free Medium without L-
Glutamine 
BioWhittaker/ UltraCULTURE 12-725F 
*Refer to Appendix A1: Making Media - DMEM + 10% FBS + PS 
 
3.5.2. Special notices 
                                                        
17 Tay, Savas. (2011). Single-cell NF-κB dynamics reveal digital activation and analog information processing in 
cells. Nature. 466(7303), 267–271. 
18 Zhang, Z., Stickney, Z., Duong, N., Curley, K., & Lu, B. (2017). AAV-based dual-reporter circuit for monitoring 
cell signaling in living human cells. Journal of Biological Engineering, 11(1), 18.  
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• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform this procedure unless the above requirements are met.  
 
3.5.3. Overview of procedure 
 
Table 3-2: Overview of procedure – Phase 2 – Verifying 3T3 NF-κB reporter. 
 Step Section 
Day 1 Seed cells 1 
Day 2 
Treat cells with TNFα  2 
Image treated cells 3 
 
 
3.5.4. Procedure 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed HEK 
293 cells onto a 4 chamber glass bottom dish at a density of 1-5x105 cells/mL 
with DMEM + 10% FBS + PS media. 
1.2. Incubate at 37°C for 24 hours. 
Day 2 
2. Treat Cells with TNFα  
2.1. Add recombinant human TNFα protein to serum-free media to create a 
concentration of 10ng/mL TNFα. 
2.2. Aspirate the media in each of the chambers. 
2.3. Carefully add 1mL serum-free media to 2 chambers and 1mL of serum-free 
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media with 10ng/mL TNFα to the other 2 chambers. 
2.4. Incubate at 37°C for 1 hour. 
3. Image treated cells 
3.1. Using a confocal microscope take phase, GFP, and RFP images of the cells at 
20x for each chamber. 
 
3.6. Materials and Methods: Verifying HEK NF-κB GFP reporter  
 
3.6.1. Materials 
 
Table 3-3: Materials – Phase 2 – Verifying HEK NF-κB GFP reporter 
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
Multiwell culture plates, 12 well 
Sigma-Aldrich/ Greiner 
CELLSTAR 
665102 
DMEM + 10% FBS + PS media* Created in lab N/A 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
Serum-Free Medium without L-
Glutamine 
BioWhittaker/ UltraCULTURE 12-725F 
Phosphate-Buffered Saline pH 7.4 
(PBS) 
Thermo Fisher Scientific AM9625 
Trypsin 0.25% with phenol red Thermo Fisher Scientific 15050065 
15 mL conical-bottom centrifuge 
tubes 
VWR 89039-666 
Disposable glass tubes 12 mm, 6 
mL 
Kimble™ / KIMAX™ 735001275 
Cytometer Setup & Tracking Beads 
FL 1-3 
BD Biosciences/ BD CS&T 661414 
Sheath, Detergent, FACSClean 
Solution Bottle, Filters 
BD Biosciences 660322 
Flow Cytometer 
BD Biosciences/ BD Accuri C6 
Plus 
661311 
*Refer to Appendix A1: Making Media - DMEM + 10% FBS + PS 
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3.6.2. Special notices 
• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform this procedure unless the above requirements are met.  
 
3.6.3. Overview of procedure 
 
Table 3-4: Overview of procedure – Phase 2 – Verifying HEK NF-κB GFP reporter  
 Step Section 
Day 1 Seed cells 1 
Day 2 Treat cells with TNFα  2 
Day 3 
Image transfected cells 3 
Flow cytometry analysis 4 
 
 
 
3.6.4. Procedure 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed cells into 
7 wells of a 12-well plate at a density of 1-5x105 cells/mL with DMEM + 10% 
FBS + PS media. 
1.1.1. Plate 1 well with HEK 293 cells and the other 6 wells with the 
HEK 293 NF-κB GFP/Luciferase Dual Reporter System cells. 
1.2. Incubate at 37°C for 24 hours. 
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Day 2 
2. Treat Cells with TNFα  
2.1. Add recombinant human TNFα protein to serum-free media to create a stock 
concentration of 10ng/mL TNFα. 
2.2. Aspirate the media in each well. 
2.3. Carefully add 1mL of new media to the 7 wells with cells. 
2.3.1. Use 10ng/mL TNFα serum-free media for 3 of the wells with the 
reporter cells. 
2.3.2. Use normal serum-free media for the other 3 wells with the 
reporter cells and the 1 well with HEK 293. 
2.4. Incubate at 37°C for 24 hours. 
Day 3 
3. Image treated cells (for each different condition) 
3.1. Using a fluorescent microscope take phase and GFP images of the cells at 4x.  
4. Flow cytometry analysis 
4.1. Carefully aspirate the media off of the dish. 
4.2. Carefully add 0.5mL of trypsin to each well with cells.  
4.3. Incubate at 37°C for 2 minutes. 
4.4. Deactivate trypsin by adding 1.5mL of DMEM + 10% FBS + PS media to one 
well. 
4.5. Collect all media in that well into a 15mL centrifuge tube. 
4.6. Repeat for remaining wells with cells. 
4.7. Centrifuge at 1500 RPM for 5 minutes. 
4.8. Carefully aspirate off the supernatant. 
4.9. Resuspend the pellet in 500-1000µL of PBS. 
4.10. Filter each sample through a 40 micron filter into a 6mL glass tube. 
4.11. Turn on the computer and flow cytometer. 
4.12. Place empty glass tube on SIP and run backwash. 
4.13. Run DI water through the flow cytometer for 2 minutes. 
4.14. Run a solution of DI water and FL1-3 tracking beads through the flow 
cytometer for 2 minutes. 
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4.15. Run each sample through the flow cytometer until 30,000-50,000 events 
have been recorded. 
4.15.1. Between each sample, run DI water through the flow cytometer for 
2 minutes. 
4.16. Run cleaning solution through the flow cytometer for 2 minutes. 
4.17. Run DI water through the flow cytometer for 2 minutes. 
4.18. Leave the glass tube with DI water on the SIP. 
 
3.7. Materials and Methods: Verifying HEK NF-κB Luciferase reporter  
 
3.7.1. Materials 
 
Table 3-5: Materials – Phase 2 – Verifying HEK NF-κB Luc reporter 
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
DMEM + 10% FBS + PS media* Created in lab N/A 
96 well plate, clear bottom Sigma-Aldrich/ Corning 3340 
Serum-Free Medium without L-
Glutamine 
BioWhittaker/ UltraCULTURE 12-725F 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
Plate reader BMG Lab Tech/ LUMIstar Omega S/N 415-1717 
Luciferase assay system w/ 
luciferase assay buffer (LAB), 
luciferase assay substrate (LAS), 
and passive lysis buffer (PLB) 
Promega E1501 
*Refer to Appendix A1: Making Media - DMEM + 10% FBS + PS 
 
3.7.2. Special notices 
• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
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• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform this procedure unless the above requirements are met.  
 
3.7.3. Overview of procedure 
 
Table 3-6: Overview of procedure –Phase 2 – Verifying HEK NF-κB Luc reporter 
 Step Section 
Day 1 Seed cells 1 
Day 2 Treat cells with TNFα  2 
Day 3 
Image transfected cells 3 
Luciferase assay 4 
 
3.7.4. Procedure 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed HEK 293 
cells into 18 wells of a 96-well plate at a density of 1-5x105 cells/mL with 
DMEM + 10% FBS + PS media. 
1.2. In the same 96-well plate, repeat 1.1 for HEK 293 NF-κB GFP/Luciferase Dual 
Reporter cells. 
1.3. Incubate at 37°C for 24 hours. 
Day 2 
2. Treat Cells with TNFα  
2.1. Add recombinant human TNFα protein to serum-free media to obtain 
concentrations of 10, 5, 1, 0.5, 0.1, and 0 ng/mL TNFα. 
2.2. Aspirate the media in each well. 
2.3. Carefully add 100µL of serum-free media to each well with the following 
concentrations of TNFα: 10, 5, 1, 0.5, 0.1, and 0 ng/mL. 
2.3.1. Each concentration is run in triplicate for both cell lines. 
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2.4. Incubate at 37°C for 24 hours. 
Day 3 
3. Image treated cells (for each different condition) 
3.1. Using a fluorescent microscope take phase and GFP images of the cells at 4x.  
4. Luciferase assay 
4.1. Prepare Luciferase Assay Reagent (LAR) by combining 10mL of LAB with an 
entire vial of LAS. Pipette up and down to mix.  
4.2. Dilute the PLB by combining stock with 4x volume of DI water. 
4.3. Add 20μL of diluted lysis buffer to each well. 
4.4. Mix with gentle rotations for 10 minutes. 
4.5. Turn on computer and plate reader. 
4.6. Set up plate reader to measure luminescence with a read time of 10 seconds. 
4.7. Quickly add 100μL of LAR to each well. 
4.8. Immediately run the plate in the plate reader. 
4.8.1. Ensure that the order in which you add the LAR is the same order 
in which the plate reader reads the samples.  
 
 
3.8. Results 
 
3.8.1. 3T3 NF-κB reporter 
Figure 3-4 shows the results of our first attempt to measure inflammatory response in a cell 
culture model using the RFP-based nuclear localization reporting system.  
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Figure 3-4: Confocal images of 3T3 p65-RFP H2B-GFP reporter. Photos were taken 1 hour after treatment with 
TNFα. The percentage of cells that present nuclear RFP is displayed on the RFP images. 
 
The images show that this reporter system was successful in indicating the effects of TNFα 
on the cell. The cells to which no TNFα was added showed no nuclear localization of p65-
RFP, as evident from the lack of yellow nuclei in Figure 3-4. Conversely, many of the cells 
to which TNFα was added show a migration of RFP to the nucleus and this is verified by 
their yellow nuclei in the overlay (Figure 3-4). Counting the number of yellow nuclei in the 
overlay indicated the reporter’s efficiency was approximately 91%. 
 
3.8.2. HEK NF-κB GFP reporter 
Figure 3-5 shows the results of our second method of measuring inflammatory response in a 
cell culture model by measuring GFP intensity of our GFP-Luc dual reporter system. 
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Figure 3-5: Flow cytometry data for HEK NF-κB GFP reporter. HEK293 cells were transfected with the 
reporter and treated with 0 or 10 ng/ml TNFα. 24 hours after treatment, images were taken (left) and the 
fluorescence was measured using flow cytometry (all graphs). 
 
Evinced in Figure 3-5-A there are two distinct populations of cells in the treatment group: 
those expressing GFP (the peak to the right of the vertical line) and those not expressing 
GFP (the peak to the left of the vertical line). The left peak was consistent with the control 
and background conditions, while the right peak showed a significant increase in 
measurable GFP intensity. Visual representations of this increase in GFP expression are 
evident in the fluorescent microscope images in Figure 3-5-B. Overall fold differences in 
the average GFP intensity of each population are displayed in Figure 3-5-C.  We saw a 
statistically significant 32-fold increase in average GFP intensity between the reporter cells 
treated with TNFα compared to those untreated. 
 
3.8.3. HEK NF-κB Luciferase reporter 
Figure 3-6 shows the results of our second method of measuring inflammatory response in a 
cell culture model by measuring luciferase expression from a dose response of TNFα using 
our GFP-Luc dual reporter system.  
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Figure 3-6: Luciferase assay for HEK NF-κB Luc reporter. The control, unmodified HEK 293 cells (green), 
provided the luminescence baseline. Each condition was run in triplicate, and error bars represent ± one standard 
deviation. 
 
There was a logarithmic trend between the concentration of TNFα and luminescence in our 
dual reporter cells as demonstrated in Figure 3-6. The TNFα dose response to the control 
group showed no significant upward trend in luciferase expression, confirming that TNFα 
on its own does not increase luminescence readings in a luminometer. We selected 1 ng/ml 
TNFα as the dose for which we will test our treatment because it is well above baseline, but 
a decrease in TNFα concentration would be clearly measurable by a decrease in 
luminescence. Also, this concentration of TNFα is still ten times higher than that found in 
Rheumatoid synovium19, making it a good choice for a proof of concept. 
 
 
 
                                                        
19 Manicourt, D., Triki, R., Fukuda, K., & Devogelaer, J. (n.d.). Levels of circulating tumor necrosis factor a and 
interleukin-6 in patients with rheumatoid arthritis Relationship to Serum Levels of Hyaluronan and Antigenic 
Keratan Sulfate, 490–499.  
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3.9. Discussion 
 
The results from the above three inflammatory reporter verification experiments have shown us 
that we can measure inflammation in a variety of ways, thus showing us the inflammation 
pathway at two distinct stages. The experiment that imaged nuclear localization was not 
repeatable during our timeframe since the images were taken during a confocal microscope demo 
session and the microscope was not delivered to the lab until after winter quarter. The flow 
cytometry experiment that measured GFP intensity was limited in the fact that our TNFR-
exosome complexes also contained GFP markers, thus the basal level GFP intensity would be 
high and any changes would be more difficult to measure. For these reasons, we chose to use the 
luciferase assay to test our therapy in the following phase of our project. 
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4. Testing Efficacy of Design 
 
 
Figure 4-1: Timeline of project phases. This chapter focuses on Phase 3. 
 
The goal of this stage was to determine whether our modified exosomes are capable of 
preventing inflammation. Using the inflammation reporter verified in Phase 2, we measured the 
effect of the modified exosomes stored from Phase 1 on the inflammatory response of live 
mammalian cells. 
 
4.1. Key constraints 
 
The key constraints for this phase of our project was primarily the quantity of exosomes. 
Although our store of exosomes was too low to run treat cells in 12-well plate for flow 
cytometry, we had enough to treat cells in a 96-well plate for a luciferase assay.  
 
4.2. Design description 
 
We designed this experiment using the luciferase assay method of monitoring inflammation for 
the reasons expressed in section 3.8 above. The luciferase assay measures the intensity of firefly 
luciferase, which increases with the initiation of the inflammation pathway after exposure to 
TNFα, as explained in section 3.7.2. Successful inhibition of inflammation would be indicated by 
a decrease in luciferase expression with the addition of treatment.  
To robustly assess the effects of our therapy, we designed an experiment with several 
controls and varying concentrations of exosomes. We also ran each group in triplicate for 
statistical significance. We added two different types of exosomes to our dual-reporter cell line; 
CD63-RFP-GFP and CD63-TNFR-GFP exosomes that were collected during Phase 1. 
Phase 1: 
Design Production
Fall 2016
Phase 2: 
Verification of 
Inflammation Reporter
Winter 2017
Phase 3: 
Testing Efficacy of 
Design
Spring 2017
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With RFP in place of the TNFR protein in our therapeutic exosomes, these exosomes could 
act as a control group to show what effect exosomes themselves have on the luciferase assay 
without the inclusion of the therapeutic TNFR protein. The CD63 TNFR-GFP exosomes were 
our therapeutic design. Each of these were added in three concentrations: 0.5 mg/ml, 0.1 mg/ml, 
and 0 mg/ml (negative control). These concentrations were selected based on previous 
experiments we did in our lab for different projects in the past. Each experimental group was run 
in media with no TNFα and 1 ng/ml TNFα. 
 
4.3. Expected results 
 
We expected that the TNFα treated wells in which we added our TNFR exosomes would have a 
decreased luciferase luminescence compared to those without exosomes by at least 50%. We 
predicted that our therapeutic exosomes would bind to TNFα, effectively reducing its 
concentration and thus reducing inflammatory response. We did not expect to see a significant 
decrease in luminescence with the addition of the control exosomes because they lacked TNFR 
to specifically bind to and soak up the TNFα added.  
 
4.4. Backup plan 
 
Our back up plan was to use one of the other reporters tested in the previous phase of the 
experiment. Though not ideal, they would be sufficient in providing a proof of concept for 
further experimentation. 
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4.5. Materials and Methods 
 
4.5.1. Materials 
 
Table 4-1: Materials – Phase 3 
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
DMEM + 10% FBS + PS media* Created in lab N/A 
96 well plate, clear bottom Sigma-Aldrich/ Corning 3340 
Serum-Free Medium without L-
Glutamine 
BioWhittaker/ UltraCULTURE 12-725F 
Recombinant Human TNFα Protein R&D Systems 210-TA-020 
CD63-TNFR-GFP exosomes Created in lab in Phase 1 N/A 
CD63-RFP-GFP exosomes Created in lab in Phase 1 N/A 
Plate reader BMG Lab Tech/ LUMIstar Omega S/N 415-1717 
Luciferase assay system w/ 
luciferase assay buffer (LAB), 
luciferase assay substrate (LAS), 
and passive lysis buffer (PLB) 
Promega E1501 
*Refer to Appendix A1: Making Media - DMEM + 10% FBS + PS 
 
4.5.2. Special notices 
• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform this procedure unless the above requirements are met.  
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4.5.3. Overview of procedure 
 
Table 4-2: Overview of procedure – Phase 3 
 Step Section 
Day 1 Seed cells 1 
Day 2 Treat cells with TNFα + exosomes 2 
Day 3 
Image transfected cells 3 
Luciferase assay 4 
 
4.5.4. Procedure 
Day 1 
1. Seed Cells 
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed cells into 
27 wells of a 96-well plate at a density of 1-5x105 cells/mL with DMEM + 10% 
FBS + PS media according to the figure below. 
 
            
            
            
            
            
            
            
            
 
Figure 4-2: Diagram for plating cells in a 96-well plate. Seed green wells with HEK GFP/Luciferase Dual 
reporter cells. 
 
1.2. Incubate at 37°C for 24 hours. 
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Day 2 
2. Treat Cells with TNFα + exosomes 
2.1. Add recombinant human TNFα protein to serum-free media to create a stock 
concentration of 1ng/mL TNFα. 
2.2. Create stock concentrations of CD63-TNFR-GFP exosomes of 0, 0.1, and 
0.5mg/mL in serum-free media. 
2.3. Repeat 6.2 in 1ng/mL TNFα serum-free media. 
2.4. Perform steps 6.2-3 for CD63-RFP-GFP exosomes. 
2.5. Aspirate the media in each well. 
2.6. Carefully add 100µL of the various serum-free media conditions to each well 
according to the following diagram. 
 
            
 0              
 0.1          1ng/mL 
 0.5          TNFα  
            
 0              
 0.1          0ng/mL 
 0.5          TNFα  
Figure 4-3: Diagram for treating cells in a 96-well plate. The concentrations of exosomes are noted on the left 
and apply to the entire row. Add the corresponding concentrations of CD63-TNFR-GFP exosomes to blue wells and 
CD63-RFP-GFP exosomes to yellow wells. The top 2 blocks should have 1ng/mL TNFα while the bottom block has 
0ng/mL TNFα.  
 
2.7. Incubate at 37°C for 24 hours. 
Day 3 
3. Image treated cells (for each different condition) 
3.1. Using a fluorescent microscope take phase and GFP images of the cells at 4x.  
4. Luciferase assay 
4.1. Lyse 
4.2. Plate reader 
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4.3. Prepare Luciferase Assay Reagent (LAR) by combining 10mL of LAB with an 
entire vial of LAS. Pipette up and down to mix.  
4.4. Dilute the PLB by combining stock with 4x volume of DI water. 
4.5. Add 20μL of diluted lysis buffer to each well. 
4.6. Mix with gentle rotations for 10 minutes. 
4.7. Turn on computer and plate reader. 
4.8. Set up plate reader to measure luminescence with a read time of 10 seconds. 
4.9. Quickly add 100μL of LAR to each well. 
4.10. Immediately run the plate in the plate reader. 
4.10.1. Ensure that the order in which you add the LAR is the same order 
in which the plate reader reads the samples.  
 
4.6. Results 
 
Figure 4-4 shows the results from the efficacy test of our TNFR exosome treatment experiment. 
 
 
Figure 4-4: Efficacy of exosome membrane bound TNFR in preventing inflammation. Each group was run in 
triplicate, and error bars represent ± one standard deviation. 
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The treatment with TNFα caused an increase in luminescence, consistent with the previous phase 
of our project, confirming that the luciferase assay was run correctly. The addition of the control 
exosomes to TNFα treated cells yielded a decrease in luminescence by about 30%. The addition 
of our treatment exosomes reduced the luciferase expression by 95%, almost to the baseline 
expression with no TNFα addition. Run in triplicate, the differences between all three conditions 
were deemed statistically significant with a P value less than 0.01 from an analysis of variance 
(ANOVA). This indicated that the both exosome groups decreased the effect of TNFα on the 
inflammatory response in our dual-reporter cells. The much larger decrease in luminescence in 
the group with our TNFR exosomes indicate that they successfully inactivated more TNFα than 
the control exosomes.  
 
4.7. Discussion 
 
The results indicate that our TNFR-exosomes were more efficacious in reducing the 
inflammatory response in our HEK 293 cells than we had expected. While we hoped for at least 
a 50% decrease, our data demonstrates a 95% decrease. We did not anticipate the reduction in 
inflammatory response from the control exosomes. However, we believe this decrease is most 
likely because the exosomes may non-specifically absorb TNFα, reducing the inflammation to a 
lesser extent than the specific binding by our TNFR-exosomes. Overall, the results clearly show 
that our product has incredible therapeutic potential and can effectively reduce the initiation of 
the inflammation pathway in this mammalian cell culture model.  
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5. Conclusion 
 
5.1. Summary 
 
The primary symptom of rheumatoid arthritis is the swelling of the synovium which causes pain 
and can lead to further joint deformity. A key player in the initiation of the inflammation 
pathway in RA is TNFα. There are a few current treatments that target TNFα; however, these 
options come with limitations including a significant immune response and/or short-term relief. 
Exosomes, however, are naturally secreted nanovesicles that could be used to avoid these 
limitations. We have confirmed that exosome membrane bound TNF-receptors have the potential 
to be an effective treatment for rheumatoid arthritis with each phase of our project.  
• Phase 1: Design Production— we demonstrated that anchoring TNFR onto tetraspanin 
CD63 allowed for production of exosomes with TNFRs. 
• Phase 2: Verification of Inflammation Reporters— we identified 3 different methods of 
measuring inflammation in live mammalian cells. 
• Phase 3: Test Efficacy of Design— using one of the reporters tested in Phase 2, we 
confirmed that the CD63-TNFR-GFP exosomes have the ability to prevent inflammation 
in live mammalian cells. 
The success of our research could lead to the development of a novel treatment of rheumatoid 
arthritis as well as serve as a foundation for further research into engineering exosomes for 
therapeutic purposes (e.g., targeted drug delivery). 
 
5.2. Future work 
 
With the success of our project thus far, we hope to further this research with the following 
endeavors tackled by us or future groups: 
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5.2.1. Creation of a stable cell line 
A stable cell line is a group of mammalian cells that permanently have a specific genetic 
modification. We are creating a line of HEK 293 cells that have been permanently modified 
to produce the CD63-TNFR-GFP exosomes. This would make manufacturing and 
collecting the modified exosomes much quicker and easier for future experimentation. 
 
5.2.2. Toxicity assay 
For a treatment that will be used in humans, it is extremely important to confirm that the 
treatment will not harm the patient. Thus, we would like to run a toxicity assay with our 
CD63-TNFR-GFP exosomes. This involves measuring the viability of mammalian cells to 
varying concentrations of our modified exosomes. 
 
5.2.3. Testing design’s ability in reversing inflammation 
We have demonstrated that our modified exosomes can prevent inflammation. However, it 
is necessary to confirm whether or not they can reverse inflammation in cells that have 
already initiated the inflammation pathway. This could be tested by adding the CD63-
TNFR-GFP exosome at after TNFα (as opposed to simultaneously). The luciferase could be 
measured at various time points: before TNFα treatment, after TNFα treatment, and several 
times after addition of CD63-TNFR-GFP exosomes. 
 
5.2.4. Verifying efficacy of design in other cell lines 
We have demonstrated that our modified exosomes have the ability to prevent inflammation 
in human embryonic kidney cells. HEK 293 cells were used for this project because they 
are easy to work with and commonly used in a research environment. However, the primary 
cells of concern in rheumatoid arthritis are cells surrounding the joints (not kidney cells). 
Thus, future groups should repeat our experimentation in cell lines relating to joints (e.g., 
chondrocytes).   
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5.2.5. Comparison to soluble TNFR 
Soluble TNFR is currently the primary treatment for RA. Thus, future groups should run an 
experiment comparing sTNFR to our CD63-TNFR-GFP exosomes in lowering levels of 
inflammation. This would indicate whether or not our design would be competitive in the 
pharmaceutical industry.  
 
5.2.6. Testing other scaffolds 
We chose tetraspanin CD63 as our scaffold for anchoring TNFRs onto the exosome surface 
because of its prevalence on the exosome surface. However, there are many other scaffolds 
that can be used with different benefits. For example, a VSV-G scaffold could be used that 
might enhance exosome production. Thus, future groups should test other possible designs 
to determine which scaffold would be the best to continue with development of a clinical 
treatment. 
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6. Engineering Standards and Realistic Constraints 
 
 
6.1. Social impact 
 
As engineers our goal was to use our knowledge and expertise to develop a product for the 
betterment of society. We hope our exosomal TNFR therapy will provide three types of societal 
benefit. 
 
6.1.1. Increased efficacy  
By anchoring the TNFR to exosome membranes, we firmly believe that the therapeutic 
effects will be greater than those with current treatments such as soluble TNFR receptors. 
This would be due to their ability to deeply penetrate the tissue and spread their effects 
throughout the joint. Should this be the case, then our therapy would benefit those receiving 
our therapy with a more significant reduction in swelling and therefore less damage and 
suffering. Should appropriate safety testing be successful (see section 6.2 for more details) 
and the product cause no harm to the patients, it is clear that this would be a net positive 
impact on the well-being of society. The only members of society who would face negative 
consequences of a safe and more efficacious treatment for RA would be those selling 
competing therapies; however their loss is heavily outweighed by the gain of the patients. 
 
6.1.2. Optimized efficiency  
Another benefit of anchoring TNFR to an exosome is the natural stability the exosome 
provides to the protein. A more stable protein does not degrade as easily and lasts longer in 
the body. Combine this with the exosomes ability to penetrate the tissue and the result is a 
more efficacious treatment that is less wasteful and longer lasting than current treatments. 
The bottom line is that a patient will need far fewer injections and far fewer wasted proteins 
than typical of a soluble TNFR therapy. This will make it easier for the patient by helping 
them save money (see section 6.3 for more details) and time, by mandating fewer doctor 
visits. Not only does this provide a social benefit by making it easier for those who are 
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already undergoing treatment with current therapies, but it will also increase the number of 
people who can afford effective treatment. 
 
6.1.3. Encourage adaptations 
One of the most impactful social benefits of our project is the potential for future adaptations 
of our work. We hope to publish our work in an impactful journal such that our project can 
act as a proof of concept for engineering therapeutic proteins onto the surface of exosomes. 
The same benefits that exosomes provided for RA treatments mentioned above could be 
applied to many other protein-based therapeutics for diseases such as cancers, alzheimer's, 
and many more. Should our research provide inspiration for further research in labs around 
the world, our project could have indirect, yet far-reaching social benefit.  
 
6.2. Health and safety concerns 
 
As with all new medical therapies, there are innumerable health and safety concerns. The lack of 
complete understanding of the human body and how it will react to novel therapeutics mandates 
a rigorous process of safety testing regulated by the FDA. In the current stage of its development, 
our project represents a preclinical efficacy study. Our experimentation indicates promising 
efficacy that will need to be replicated in various cell types and with various reporters. This data 
will then have to be compared to similar tests run using the current leading therapy (soluble 
TNFR). Once further testing has confirmed the improved efficacy of our novel therapy, then 
safety testing can begin. 
The first stage of safety testing will most likely involve a toxicity assay in a mammalian cell 
culture model with various human cell types. Then FDA clinical trials begin with Phase 0, 
animal models, for both safety and efficacy testing. This is followed by four phases of clinical 
trials on human subjects. Because such trials are far beyond the scope of our project, they would 
need to be taken up by another lab with more resources. Nevertheless, the regulations in place by 
the FDA will help ensure that if a clinical therapy evolves from our project it is safe and will not 
cause more harm to those who will receive it. 
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6.3. Economic 
 
We feel optimistic about the financial prospects of our project. However, as with most advances 
in the medical field, there will be high research and development costs and a sizeable overhead. 
Although we anticipate that the necessity for less frequent injections (as mentioned in section 
6.1.2, above) will reduce the cost to the consumer in the long run, it will not reduce the cost to 
develop or manufacture the product. The costs involved with meeting the FDA requirements 
(mentioned in section 6.2, above) are often quite large. Nevertheless, this is an economic 
obstacle faced by all up-and-coming therapies. 
It might be assumed that because of the reduced frequency of injections that the costly 
overhead would yield a lower net profit, but we anticipate that the reduced cost to consumer will 
widen the market to encompass those who are not able to afford current treatment methods. This 
would make up for any presumed losses by increasing the number of injections sold while 
having a larger overall benefit to society. Thus we believe that the benefits of our novel therapy 
will make it desirable enough to be pursued by a successful pharmaceutical company once the 
proof of concept is firmly established. Our optimism has led us to pursue a patent on our therapy 
that we believe could be fruitful in the coming years. 
 
6.4. Manufacturability 
 
Manufacturing of our therapy remains to be the most significant roadblock. At this current stage, 
the exosome manufacturing method that we used for our product (see section 2.1 for details) is 
not optimized. It is inefficient and uses large quantities of resources to obtain small amounts of 
exosomes. This method is sufficient for proof-of-concept research such as ours, yet optimization 
will be necessary for mass production in the later stages of the therapy’s development. 
Fortunately, our literature studies have indicated that it is safe to assume that with the publication 
of our research and with the work of others who are beginning to use exosomes for therapeutic 
purposes, a more efficient exosome harvesting method will soon be pioneered. 
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6.5. Ethical Implications 
 
6.5.1. Ethical justification 
At the beginning of the year, we met to discuss our interests and pick project. During this 
discussion, it was agreed that we wanted to focus on a project that accomplished two goals: 
(1) progressed scientific understanding and (2) laid the groundwork for the development of 
a novel medical therapy. Our main driver for these goals was our desire to help those 
suffering from diseases or disorders. We decided to pursue exosomes due to their promising 
therapeutic nature and because they have yet to be incorporated into a successful therapy. 
Our efforts would therefore contribute to the advancement of leading edge biomedical 
engineering. Rheumatoid arthritis in particular was our focus because it is a widespread and 
debilitating disease for which a therapeutic advancement would directly help many patients 
by reducing their pain, suffering, and the physical damage associated with inflammation.  
We analyzed the moral aspects of this project from a compounded ethical framework, 
assessing the project’s ethicality from a utilitarian, rights, justice, virtue, and common good 
standpoint. Using the utilitarian approach, we hoped our success would yield benefit to the 
millions who suffer from RA or any other disease that our exosomal therapeutic techniques 
may inspire a therapy for. Considering a rights approach we hoped our success would 
increase patients’ access to their right good health. From a justice viewpoint, we hoped that 
in making a longer lasting therapeutic injection, we would allow for a more affordable 
treatment that would result in a more just distribution of treatment for those who currently 
cannot afford it. From a virtue ethics approach, we felt that by using our expertise in 
biological sciences we were being our best selves by committing our work to alleviating the 
suffering of others. Lastly, we hoped to benefit the common good with our therapy by 
contributing to the progress of the medical field and providing a therapy for RA. 
 
6.5.2. Virtues of a good engineer 
Through this project we have learned to incorporate the following ethical habits, as 
discussed by Charles Harris in his article “The Good Engineer: Giving Virtue Its Due in 
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Engineering Ethics.”20 
6.5.2.1. Techno-social sensitivity 
We considered the interplay between technology and society; that technological 
changes have an effect on society and societal changes have an effect on 
technology. It was obvious how society has advanced technology—as is 
frequently said, “necessity is the mother of invention,” – and we saw how there 
was a need for cheaper and more effective RA treatments in our society and 
sought to develop a technology to accommodate that. We then hoped that with our 
technology we would yield societal benefit by helping those suffering with RA 
and by spurring research to help others suffering from other diseases and 
conditions. 
6.5.2.2. Commitment to the public good 
As mentioned in section 6.5.1 above, the motivation behind our project was 
primarily to help those suffering and to advance medical therapeutic techniques. 
We firmly believe that our research will allow this to happen, and in turn have a 
positive effect on the public. 
6.5.2.3. Teamwork 
In working together, we have learned the values that allow for strong teamwork. 
Primarily is stressing effective communication. This not only encompasses clear 
note taking and email conversations, but also communicating thoughts regarding 
the project. As a group of two, communication was relatively straightforward and 
helped with the success of our project. Another requirement is delegation and 
trust, which we achieved by distributing the workload fairly and keeping each 
other apprised of issues and situations. 
 
6.5.3. Safety and risk assessment 
There are two aspects to safety and risk assessment when ethically considering a project. 
First is the safety to those working on the project, we addressed this by completing the lab 
safety training and rigidly abiding by the guidelines set out by the Environmental Health 
                                                        
20 Harris, Charles E. "The Good Engineer: Giving Virtue its Due in Engineering Ethics." Science and Engineering 
Ethics 14, no. 2 (2008): 153-64. 
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and Safety department at Santa Clara University. Secondly, we had to consider the safety of 
our product on those who would be using it. Unfortunately, due to our limited resources and 
time, we were only able to establish a proof-of-concept and cell culture model in our 
project. However, as discussed in section 6.2, our project’s future holds a rigorous course of 
safety testing as it would seek to obtain FDA approval. 
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Appendix A: Additional Materials and Methods 
 
 
Special Notices 
• Proper laboratory attire and practice (further explained in the SCU EHS guidelines) is 
required. 
• Safe and proper aseptic technique is required for this procedure. 
• All reagent and cell handling is to be done in the fume hood. 
• No lids or caps are to be left open unless presently in use. 
• When not in use, live cells are stored in an incubator (5% CO2, 37°C). 
• Do NOT attempt to perform any procedures unless the above requirements are met.  
 
 
Appendix A1: Making Media – DMEM + 10% FBS + PS 
 
A1-A. Materials 
 
Table A-1: Materials for making DMEM + 10% FBS + PS. 
Material Company/ Brand Model # 
Dulbecco’s Modified Eagle 
Medium with L-Glutamine 
(DMEM) 
Thermo Fisher Scientific/ 
Gibco 
11965092 
Fetal bovine serum (FBS) 
Thermo Fisher Scientific/ 
Gibco 
10438034 
Penicillin-Streptomycin (PS) 
Thermo Fisher Scientific/ 
Gibco 
15140122 
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A1-B. Methods 
 
1. Add 50mL of fetal bovine serum into 1 500mL bottle of Dulbecco’s Modified Eagle 
Medium with L-Glutamine. 
2. Add 5mL of Penicillin-Streptomycin to the combined FBS and DMEM. 
3. Mix thoroughly. 
4. Store at 4°C until needed. 
 
Appendix A2: Passaging Mammalian Cells  
 
A2-A. Materials 
 
Table A-2: Materials for passaging mammalian cells. 
Material Company/ Brand Model # 
DMEM + 10% FBS + PS 
media* 
Thermo Fisher Scientific/ 
Gibco 
11965092 
Phosphate-Buffered Saline 
pH 7.4 (PBS) 
Thermo Fisher Scientific AM9625 
Trypsin 0.25% with phenol 
red 
Thermo Fisher Scientific 15050065 
15 mL conical-bottom 
centrifuge tubes 
VWR 89039-666 
*  Refer to Appendix A1: Making Media – DMEM + 10% FBS + PS 
 
A2-B: Methods 
 
1. Retrieve 60mmx15mm dish with cells from incubator. 
2. Carefully aspirate media off of dish. 
3. Carefully wash cells by adding 3mL of PBS. 
4. Carefully aspirate off PBS of dish. 
5. Add 1.5mL trypsin into dish. 
6. Incubate at 37°C for 2 minutes. 
7. Deactivate trypsin by adding 4.5mL of DMEM + 10% FBS + PS media to the dish. 
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8. Collect all media in the dish into a 15mL centrifuge tube. 
9. Centrifuge at 1500 RPM for 5 minutes. 
10. Aspirate off the supernatant. 
11. Resuspend the pellet in DMEM + 10% FBS + PS. 
12. Plate as desired. 
 
Appendix A3: Transfection 
 
A3-A. Materials 
 
Table A-3: Materials for transfection. 
Material Company/ Brand Model # 
Passaging Mammalian Cells 
Materials (Appendix A2-A) 
  
Transfection Reagent 
Thermo Fisher Scientific/ 
Lipofectamine 2000 
11668019 
Microcentrifuge tubes 
Sigma-Aldrich/ Eppendorf 
Safe-Lock 
T9661 
Reduced Serum Medium 
Thermo Fisher Scientific/ 
Opti-MEM 
31985070 
DNA plasmid of choice   
 
 
A3-B. Methods 
 
1. Passage according to Appendix A2: Passaging Mammalian Cells onto the desired dish/ 
well plate. 
a. Volumes for the following steps depend on the dish or well plate used and are 
specified in the Table A-4. 
 
 
 
55 
 
Table A-4: Specified volumes for transfections. 
 Reduced-Serum Media Transfection Reagent DNA plasmid 
12 well plate 100 ul / well 5 µl / well 1-3 µg / well 
145mmx20mm dish 1 mL 60 µl 30-40 µg 
 
2. Incubate at 37°C for 24 hours. 
3. After 24 hours, combine reduced-serum media and transfection reagent in a 
microcentrifuge tube. 
4. Incubate at room temperature for 5 minutes. 
5. Carefully add DNA plasmid into the reduced-serum media and transfection reagent 
mixture. 
6. Incubate at room temperature for 20 minutes.  
7. Carefully add the mixture to the dish/ well. 
8. Incubate the dish/ well plate at 37° for 24 hours. 
 
